HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ERC-08-0084v1 15/4/841    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Zhu, M.-L. Articles by Kyprianou, N. Search for Related Content PubMed PubMed Citation Articles by Zhu, M.-L. Articles by Kyprianou, N.

Departments of Urology and Toxicology, University of Kentucky College of Medicine, University of Kentucky Medical Center, Combs Research Building Room 306, Lexington, Kentucky 40536, USA

(Correspondence should be addressed to N Kyprianou; Email: nkypr2{at}uky.edu)

Androgens promote the growth and differentiation of prostate cells through ligand activation of the androgen receptor (AR). Sensitization of the androgenic response by multifunctional growth factor signaling pathways is one of the mechanisms via which AR contributes to the emergence of androgen-independent prostate tumors. The ability of AR to cross-talk with key growth factor signaling events toward the regulation of cell cycle, apoptosis, and differentiation outcomes in prostate cancer cells is established. In this paper, we review the functional interaction between AR and an array of growth factor signal transduction events (including epidermal growth factor; fibroblast growth factor; IGF1; vascular endothelial growth factor; transforming growth factor-β) in prostate tumors. The significance of this derailed cross-talk between androgens and key signaling networks in prostate cancer progression and its value as a therapeutic forum targeting androgen-independent metastatic prostate cancer is discussed.

This article has been cited by other articles:

				H. Masuyama, H. Nakatsukasa, and Y. Hiramatsu Effect of Oncostatin M on Uridine Diphosphate-5'-Glucuronosyltransferase 1A1 through Cross Talk with Constitutive Androstane Receptor Mol. Endocrinol., April 1, 2010; 24(4): 745 - 753. [Abstract] [Full Text] [PDF]

				M.-L. Zhu and N. Kyprianou Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells FASEB J, March 1, 2010; 24(3): 769 - 777. [Abstract] [Full Text] [PDF]

				R. Narayanan, M. Yepuru, A. T. Szafran, M. Szwarc, C. E. Bohl, N. L. Young, D. D. Miller, M. A. Mancini, and J. T. Dalton Discovery and Mechanistic Characterization of a Novel Selective Nuclear Androgen Receptor Exporter for the Treatment of Prostate Cancer Cancer Res., January 15, 2010; 70(2): 842 - 851. [Abstract] [Full Text] [PDF]

				H. Ishiguro, K. Akimoto, Y. Nagashima, Y. Kojima, T. Sasaki, Y. Ishiguro-Imagawa, N. Nakaigawa, S. Ohno, Y. Kubota, and H. Uemura aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 PNAS, September 22, 2009; 106(38): 16369 - 16374. [Abstract] [Full Text] [PDF]

				K. E. Knudsen and H. I. Scher Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer Clin. Cancer Res., August 1, 2009; 15(15): 4792 - 4798. [Abstract] [Full Text] [PDF]